Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.430
-0.030 (-1.22%)
Apr 22, 2026, 12:06 PM EDT - Market open
Alector Employees
Alector had 103 employees as of December 31, 2025. The number of employees decreased by 135 or -56.72% compared to the previous year.
Employees
103
Change
-135
Growth
-56.72%
Revenue / Employee
$204,320
Profits / Employee
-$1,387,660
Market Cap
268.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | -135 | -56.72% |
| Sep 30, 2025 | 156 | -85 | -35.27% |
| Jun 30, 2025 | 163 | -82 | -33.47% |
| Mar 31, 2025 | 175 | -69 | -28.28% |
| Dec 31, 2024 | 238 | -6 | -2.46% |
| Sep 30, 2024 | 241 | -5 | -2.03% |
| Jun 30, 2024 | 245 | 6 | 2.51% |
| Mar 31, 2024 | 244 | -29 | -10.62% |
| Dec 31, 2023 | 244 | -29 | -10.62% |
| Sep 30, 2023 | 246 | -23 | -8.55% |
| Jun 30, 2023 | 239 | -30 | -11.15% |
| Mar 31, 2023 | 273 | 36 | 15.19% |
| Dec 31, 2022 | 273 | 65 | 31.25% |
| Sep 30, 2022 | 269 | 84 | 45.41% |
| Jun 30, 2022 | 269 | 85 | 46.20% |
| Mar 31, 2022 | 237 | 56 | 30.94% |
| Dec 31, 2021 | 208 | 37 | 21.64% |
| Sep 30, 2021 | 185 | 23 | 14.20% |
| Jun 30, 2021 | 184 | 31 | 20.26% |
| Mar 31, 2021 | 181 | 55 | 43.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Protara Therapeutics | 46 |
| Inhibikase Therapeutics | 35 |
ALEC News
- 7 weeks ago - Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Alector to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - GlobeNewsWire
- 5 months ago - Alector to Participate in the Bank of America CNS Therapeutics Conference - GlobeNewsWire
- 5 months ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 months ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 6 months ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire